Kim Hyun Jung, Choi Sujin, Choe Young June
Medical Affairs, Sanofi, Seoul, Korea.
Allergy Immunology Center, Korea University, Seoul, Korea.
Infect Chemother. 2025 Mar;57(1):31-37. doi: 10.3947/ic.2024.0122.
Respiratory syncytial virus (RSV) poses a significant threat to infants and young children in Korea and globally. Current preventive measures, such as palivizumab, have limitations, necessitating the exploration of new strategies. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising option for protecting all infants from RSV. Clinical trials and real-world evidence support its effectiveness in reducing RSV-related hospitalizations. The economic burden of RSV infection in Korea underscores the need for cost-effective interventions. While several RSV vaccines are under development, none are currently available in Korea. Maternal immunization programs and vaccines for older infants offer potential avenues for expanding protection. This review highlights the evolving landscape of RSV prevention, with a shift towards nirsevimab and future vaccines. Further research is crucial to understand the long-term consequences of RSV infection and develop comprehensive prevention strategies tailored to the Korean population.
呼吸道合胞病毒（RSV）对韩国及全球的婴幼儿构成重大威胁。目前的预防措施，如帕利珠单抗，存在局限性，因此有必要探索新的策略。Nirsevimab是一种长效单克隆抗体，已成为保护所有婴儿免受RSV感染的有前景的选择。临床试验和真实世界证据支持其在减少RSV相关住院方面的有效性。RSV感染在韩国造成的经济负担凸显了采取具有成本效益的干预措施的必要性。虽然几种RSV疫苗正在研发中，但韩国目前尚无可用疫苗。母体免疫计划和针对较大婴儿的疫苗为扩大保护范围提供了潜在途径。本综述强调了RSV预防格局的不断演变，正朝着Nirsevimab和未来疫苗的方向发展。进一步的研究对于了解RSV感染的长期后果以及制定针对韩国人群的综合预防策略至关重要。
